Duru G - Search Results

1

Advantages and limitations of utility assessment methods in rheumatoid arthritis.

Beresniak A, Russell AS, Haraoui B, Bessette L, Bombardier C, Duru G. Beresniak A, et al. Among authors: duru g. J Rheumatol. 2007 Nov;34(11):2193-200. Epub 2007 Oct 15. J Rheumatol. 2007. PMID: 17937471

2

Limitations of the methods used for calculating quality-adjusted life-year values.

Duru G, Auray JP, Béresniak A, Lamure M, Paine A, Nicoloyannis N. Duru G, et al. Pharmacoeconomics. 2002;20(7):463-73. doi: 10.2165/00019053-200220070-00004. Pharmacoeconomics. 2002. PMID: 12093302

3

Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument.

Beresniak A, Auray JP, Duru G, Aractingi S, Krueger GG, Talarico S, Tsutani K, Dupont D, de Linares Y. Beresniak A, et al. Among authors: duru g. J Cosmet Dermatol. 2015 Sep;14(3):260-5. doi: 10.1111/jocd.12156. Epub 2015 Jul 2. J Cosmet Dermatol. 2015. PMID: 26133392

4

Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL instrument.

Beresniak A, Auray JP, Duru G, Aractingi S, Krueger GG, Talarico S, Adam AS, Piot B, Dupont D, de Linares Y. Beresniak A, et al. Among authors: duru g. J Cosmet Laser Ther. 2015;17(6):313-7. doi: 10.3109/14764172.2015.1039034. Epub 2015 Jul 2. J Cosmet Laser Ther. 2015. PMID: 25968164

5

Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.

Beresniak A, Medina-Lara A, Auray JP, De Wever A, Praet JC, Tarricone R, Torbica A, Dupont D, Lamure M, Duru G. Beresniak A, et al. Among authors: duru g. Pharmacoeconomics. 2015 Jan;33(1):61-9. doi: 10.1007/s40273-014-0216-0. Pharmacoeconomics. 2015. PMID: 25230587

6

Validation of a new international quality-of-life instrument specific to cosmetics and physical appearance: BeautyQoL questionnaire.

Beresniak A, de Linares Y, Krueger GG, Talarico S, Tsutani K, Duru G, Berger G. Beresniak A, et al. Among authors: duru g. Arch Dermatol. 2012 Nov;148(11):1275-82. doi: 10.1001/archdermatol.2012.2696. Arch Dermatol. 2012. PMID: 23165832

7

Relationships between black tea consumption and key health indicators in the world: an ecological study.

Beresniak A, Duru G, Berger G, Bremond-Gignac D. Beresniak A, et al. Among authors: duru g. BMJ Open. 2012 Nov 8;2(6):e000648. doi: 10.1136/bmjopen-2011-000648. Print 2012. BMJ Open. 2012. PMID: 23138107 Free PMC article.

8

Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK.

Daya S, Ledger W, Auray JP, Duru G, Silverberg K, Wikland M, Bouzayen R, Howles CM, Beresniak A. Daya S, et al. Among authors: duru g. Hum Reprod. 2001 Dec;16(12):2563-9. doi: 10.1093/humrep/16.12.2563. Hum Reprod. 2001. PMID: 11726575

9

Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach.

Briand S, Beresniak A, Nguyen T, Yonli T, Duru G, Kambire C, Perea W; Yellow Fever Risk Assessment Group (YF-RAG). Briand S, et al. Among authors: duru g. PLoS Negl Trop Dis. 2009 Jul 14;3(7):e483. doi: 10.1371/journal.pntd.0000483. PLoS Negl Trop Dis. 2009. PMID: 19597548 Free PMC article.

10

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A. Bresse X, et al. Among authors: duru g. Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):393-406. doi: 10.1586/erp.13.19. Epub 2013 Mar 28. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23537397

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters